Diligence memo · auto-generated · as of July 2, 2026
SCOLR Pharma, Inc.
SCOLR Pharma, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
SCOLR Pharma, Inc. operates in Pharmaceuticals, based in BELLEVUE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SCOLR Pharma, Inc. has raised $6.6M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.1M on 2010-03-04.
Most recent recorded round closed around 2012-05-04.
Valuation (modeled)modeled
Provath models SCOLR Pharma, Inc. at approximately $9.5M (range $353K–$52M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.05× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 14.2 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 47% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.